EXAGEN INC.
No enriched coverage for $XGN in the last 7 days.
No SEC Form 4 filings for $XGN in the last 30 days.
See all $XGN insider activity →Exagen (NASDAQ:XGN) reported record Q2 2026 revenue of $19.9 million, up 16% year over year, driven by an 11% rise in AVISE CTD testing volume and a 4% higher trailing twelve-month average selling price to $446 per test. Adjusted EBITDA loss narrowed to $0.1 million. Exagen raised full-year 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million.
Exagen Inc. reported record Q2 2026 revenue of $19.9 million, up 16% year over year, helped by record AVISE test volumes and higher trailing 12-month ASP near $446. The company raised full-year 2026 revenue guidance to $72 million to $75 million and expects adjusted EBITDA breakeven around $80 million of revenue. Exagen also discussed collections, reimbursement timing, and a myositis product launch in early 2027.
Exagen Inc. (Nasdaq: XGN) reported Q2 2026 results for the quarter ended June 30. Total revenue rose to $19.9 million, up 16% year over year, with AVISE CTD test volume up 11% and trailing twelve-month ASP at $446. Adjusted EBITDA loss narrowed to $0.1 million. Full-year 2026 revenue guidance increased to $72 to $75 million.
Recent XGN coverage spans financial news, earnings and corporate actions.
Raised FY revenue outlook alongside improving margins and adjusted EBITDA suggests improving operating leverage and demand durability for AVISE tests.
Guidance raise and a clearer path to EBITDA breakeven should support near-term valuation, but second-half seasonality and reimbursement timing remain key swing factors.
Guidance increase plus margin/EBITDA improvement suggests improving operating leverage, which can re-rate near-term expectations for profitability and cash burn.
Guidance increase plus improved adjusted EBITDA loss and cash position are near-term positives for XGN’s growth and path to profitability.
Routine corporate governance vote disclosure; limited fundamental signal beyond confirming outcomes.
alphai scores every news story that mentions XGN with an AI model for sentiment and relevance, and aggregates insider trades from EXAGEN INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Exagen (NASDAQ:XGN) reported record Q2 2026 revenue of $19.9 million, up 16% year over year, driven by an 11% rise in AVISE CTD testing volume and a 4% higher trailing twelve-month average selling price to $446 per test. Adjusted EBITDA loss narrowed to $0.1 million. Exagen raised full-year 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million.
4 min readExagen Inc. reported record Q2 2026 revenue of $19.9 million, up 16% year over year, helped by record AVISE test volumes and higher trailing 12-month ASP near $446. The company raised full-year 2026 revenue guidance to $72 million to $75 million and expects adjusted EBITDA breakeven around $80 million of revenue. Exagen also discussed collections, reimbursement timing, and a myositis product launch in early 2027.
6 min readExagen Inc. (Nasdaq: XGN) reported Q2 2026 results for the quarter ended June 30. Total revenue rose to $19.9 million, up 16% year over year, with AVISE CTD test volume up 11% and trailing twelve-month ASP at $446. Adjusted EBITDA loss narrowed to $0.1 million. Full-year 2026 revenue guidance increased to $72 to $75 million.
5 min readEXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026exagenearningspressr.htm EX-99.1 Document Exagen Inc. Reports Second Quarter 2026 Financial Results Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased
4 min readEXAGEN INC. (XGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. exdx-20260609 0001274737 FALSE 0001274737 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min readExagen Inc. (NASDAQ:XGN) reported strong first-quarter results with revenues exceeding analyst forecasts, leading to lower statutory losses than anticipated. Analysts have consequently updated their forecasts, with a moderate uplift in sentiment regarding loss per share, though the average price target remains steady at US$8.67. Despite the positive adjustments, Exagen's projected revenue growth of 6.3% annually until 2026 is expected to trail the broader industry's 22% annual growth.
3 min readExagen Inc. will release its first-quarter financial results for the period ended March 31, 2026, before the market opens on Monday, May 11, 2026. Following the release, President and CEO John Aballi and CFO Jeff Black will host a conference call to discuss the results. The company, a provider of innovative autoimmune testing, will also make the webcast and a replay available on its investor relations website.
2 min readExagen Inc. (NASDAQ: XGN) is considered one of the best penny stocks to watch, with analysts assigning over 80% "Buy" ratings and a consensus price target of $10, implying a significant 235.01% upside. Despite a recent price target reduction by Craig-Hallum due to lower-than-expected average selling prices, the company reported a 20% year-over-year revenue increase in Q4 2025 and ended the year with $32 million in cash. Exagen, a diagnostics company focusing on autoimmune diseases, is guiding 2026 revenue between $70 million and $73 million, demonstrating a push toward profitable growth.
3 min readExagen Inc. (NASDAQ:XGN) reported record 2025 annual revenue of $66.58 million, a 20% increase over the previous year, driven by higher test volumes and improved pricing for its AVISE CTD test. Despite missing Q4 2025 revenue and EPS estimates, the company highlighted significant operational achievements and a strengthened financial position, ending the year with $32.2 million in cash. Exagen provided 2026 revenue guidance of $70 million to $73 million, slightly below analyst consensus, as it continues its path toward cash flow positivity.
3 min readExagen (NASDAQ:XGN) announced its quarterly earnings, reporting an EPS of ($0.20) which matched analyst estimates, and revenue of $16.63 million, exceeding expectations. The article also details the company's financial performance metrics, recent insider stock sales, significant hedge fund activity, and current analyst ratings, which suggest a "Moderate Buy" consensus.
3 min read
